260 related articles for article (PubMed ID: 12734341)
1. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
[TBL] [Abstract][Full Text] [Related]
3. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.
van der Stoep N; Biesta P; Quinten E; van den Elsen PJ
Int J Cancer; 2002 Feb; 97(4):501-7. PubMed ID: 11802213
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
7. X box-like sequences in the MHC class II region maintain regulatory function.
Gomez JA; Majumder P; Nagarajan UM; Boss JM
J Immunol; 2005 Jul; 175(2):1030-40. PubMed ID: 16002703
[TBL] [Abstract][Full Text] [Related]
8. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
[TBL] [Abstract][Full Text] [Related]
9. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
10. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
[TBL] [Abstract][Full Text] [Related]
11. MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation.
Zhou X; Jiang Y; Lu L; Ding Q; Jiao Z; Zhou Y; Xin L; Chou KY
Immunology; 2007 Dec; 122(4):476-85. PubMed ID: 17645498
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.
Lu Y; Tschickardt ME; Schmidt BJ; Blanck G
Immunol Cell Biol; 1997 Aug; 75(4):325-32. PubMed ID: 9315472
[TBL] [Abstract][Full Text] [Related]
13. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter.
Beresford GW; Boss JM
Nat Immunol; 2001 Jul; 2(7):652-7. PubMed ID: 11429551
[TBL] [Abstract][Full Text] [Related]
14. Increased binding of IFN regulating factor 1 mediates the synergistic induction of CIITA by IFN-gamma and tumor necrosis factor-alpha in human thyroid carcinoma cells.
Rahat MA; Chernichovski I; Lahat N
Int Immunol; 2001 Nov; 13(11):1423-32. PubMed ID: 11675374
[TBL] [Abstract][Full Text] [Related]
15. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
[TBL] [Abstract][Full Text] [Related]
16. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.
Morris AC; Beresford GW; Mooney MR; Boss JM
Mol Cell Biol; 2002 Jul; 22(13):4781-91. PubMed ID: 12052885
[TBL] [Abstract][Full Text] [Related]
18. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.
Murphy SP; Holtz R; Lewandowski N; Tomasi TB; Fuji H
J Immunol; 2002 Sep; 169(6):3085-93. PubMed ID: 12218125
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
20. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]